Demand for congenital hyperinsulinism treatment will increase through 2036, with drug therapy at 68.5% of the treatment method segment in 2026. Hospitals lead the end-user segment with a 74.2% share. The market was valued at USD 112.4 million in 2025 and is expected to be worth USD 213.37 million by 2036.